CA3224118A1 - Pharmaceutical compositions of a b7-h3 antibody and use of the same - Google Patents

Pharmaceutical compositions of a b7-h3 antibody and use of the same Download PDF

Info

Publication number
CA3224118A1
CA3224118A1 CA3224118A CA3224118A CA3224118A1 CA 3224118 A1 CA3224118 A1 CA 3224118A1 CA 3224118 A CA3224118 A CA 3224118A CA 3224118 A CA3224118 A CA 3224118A CA 3224118 A1 CA3224118 A1 CA 3224118A1
Authority
CA
Canada
Prior art keywords
cancer
pharmaceutical composition
enoblituzumab
composition
container
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3224118A
Other languages
English (en)
French (fr)
Inventor
Yan Zhou
Krishnan SAMPATHKUMAR
Stephen James Burke
Xiaoyan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CA3224118A1 publication Critical patent/CA3224118A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA3224118A 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same Pending CA3224118A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
US63/222,750 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (1)

Publication Number Publication Date
CA3224118A1 true CA3224118A1 (en) 2023-01-19

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3224118A Pending CA3224118A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Country Status (11)

Country Link
US (1) US20240336687A1 (https=)
EP (1) EP4370155A4 (https=)
JP (1) JP2024526773A (https=)
KR (1) KR20240038005A (https=)
CN (1) CN117715657A (https=)
AU (1) AU2022310668A1 (https=)
CA (1) CA3224118A1 (https=)
IL (1) IL310187A (https=)
MX (1) MX2024000690A (https=)
TW (1) TW202310874A (https=)
WO (1) WO2023288173A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2019246312A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
BR112022019073A2 (pt) * 2020-03-25 2022-11-08 Jiangsu Hengrui Pharmaceuticals Co Ltd Composição farmacêutica que compreende conjugado anticorpo-fármaco e uso da mesma

Also Published As

Publication number Publication date
AU2022310668A1 (en) 2024-01-18
IL310187A (en) 2024-03-01
MX2024000690A (es) 2024-02-07
WO2023288173A1 (en) 2023-01-19
EP4370155A4 (en) 2025-06-11
JP2024526773A (ja) 2024-07-19
CN117715657A (zh) 2024-03-15
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
EP4370155A1 (en) 2024-05-22
TW202310874A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
US20150239970A1 (en) Stable, Low Viscosity Antibody Formulation
TWI764097B (zh) 包含抗cd47抗體的製劑及其製備方法和用途
ES2668900T3 (es) Formulaciones estabilizadas que contienen anticuerpos anti-Dll4
TW202206102A (zh) Pd-l1/lag-3雙特異性抗體製劑及其製備方法和用途
CA3224118A1 (en) Pharmaceutical compositions of a b7-h3 antibody and use of the same
US12364756B2 (en) Pharmaceutical compositions of a PD-1 antibody and use of the same
US11459399B2 (en) Pharmaceutical compositions of a HER2/neu antibody and use of the same
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
US20230053747A1 (en) Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same
EP4620483A1 (en) Pharmaceutical composition comprising anti-rankl-ngf bispecific antibodies
WO2022120014A1 (en) Pharmaceutical compositions of a her2/neu antibody and use of the same
HK40112469A (zh) Pd-1抗体的药物组合物及其用途
CN116916952A (zh) HER2/neu抗体的药物组合物及其用途
ES2702246T3 (es) Formulaciones de agente de unión IgG4 estables
HK40102521A (zh) Her2/neu抗体的药物组合物及其用途
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
TR2025000822T2 (tr) Anti̇-cd20 anti̇kor farmasöti̇k bi̇leşi̇mi̇ ve bunun kullanimi
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
BR112021015034B1 (pt) Formulação de anticorpo terapêutico

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610